Clay Siegall is the founder and CEO of Seattle Genetics. Since inception 18 years ago, Mr. Siegall is working around the clock to ensure he transforms the firm from being biotech into a pharmaceutical company. Close to two decades, Seattle Genetics has been deeply involved in the research of human antibody, looking for ways to turn them into viable drugs that can be used to treat cancer.
Many biotech companies have failed to walk the whole journey of mutating from biotech into pharmaceuticals, but for Clay Siegall, he is determined to taking Seattle Genetics to where its predecessors have failed. Clay’s determination is evident from the milestone the company has achieved in the past and recent years. Seattle Genetics has grown at an unprecedented rate to become a top biotech company in Washington. The number of employees has increased exponentially to 900 and plans are underway to increase the current manpower by 200 employees. The market value of the biotech firm has also soared to over $10 billion. Starting 2014 to 2016 the company’s sales increased by 46%. Similarly, the firm reported that its stock price jumped from $20 to $66.
Adcetris is the inaugural drug from the company. According to the firm, the drug is used to treat a medical condition known as Hodgkin lymphoma, a type of lymph system cancer that has the capacity of spreading to other body parts. Currently, the drug is undergoing tests before it is released to the market for sale. Apart from this flagship drug, Clay Siegall says that there are more drugs under development, a clear indication that the company is focused on growing into a big business. Recently, Mr. Siegall opened an office in Switzerland, to enable the company market its new drugs to the international front.
Siegall says that his success in business is hinged on the inspiration and imitation he drew from Art Levinson, a founder of Genentech and the current chairperson of Apple. In the early stages of his business, Siegall heavy borrowed from what Genentech was doing, a move that significantly helped move Seattle Genetics to its current state.
Clay Siegall holds a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics. Before founding Seattle Genetics, he worked at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior he served at the National Cancer Institute and the National Institutes of Health. Siegall also sits on the boards of many companies and he has authored over 70 publications. Additionally, he holds several patents.